

Medicare Part D Formularies (Table 2)**(MA-PD alone and compared to PDP, excluding SNP, for 30-day supply only)**

Report on CMS formulary files (January 2025). All calculations are percentages of formularies, except for co-pay, which is in dollars, and coinsurance, which is the percentage of drug price.

MA-PD formulary report

Difference: For MA-PD relative to PDP, >0 means higher in MA-PD

Drugs selected for Medicare Drug Price Negotiation in 2026**Non-specialty drugs, typically with co-pay****Non-specialty drugs, typically with co-pay**

Generic (brand name)/(USP class (USP category))/protected class	On formulary	Without prior authorization	Tier 3 or lower	Average co-pay	Generic (brand name)/(USP class (USP category))/protected class	On formulary	Without prior authorization	Tier 3 or lower	Average co-pay
apixaban (Eliquis)/blood products (anticoagulants)	100	100	98	\$ 43	apixaban (Eliquis)/blood products (anticoagulants)	0	0	-2	\$ (2)
dapagliflozin propanediol (Farxiga)/blood glucose regulators (antidiabetic agents)	96	100	86	\$ 37	dapagliflozin propanediol (Farxiga)/blood glucose regulators (antidiabetic agents)	-4	0	7	\$ (9)
empagliflozin (Jardiance)/blood glucose regulators (antidiabetic agents)	100	100	100	\$ 37	empagliflozin (Jardiance)/blood glucose regulators (antidiabetic agents)	0	0	0	\$ (9)
insulin aspart (Fiasp/Novolog)/blood glucose regulators (insulins)	66	100	98	\$ 37	insulin aspart (Fiasp/Novolog)/blood glucose regulators (insulins)	0	0	-2	\$ (9)
rivaroxaban (Xarelto)/blood products (anticoagulants)	100	100	98	\$ 44	rivaroxaban (Xarelto)/blood products (anticoagulants)	0	0	-2	\$ (1)
sacubitril/valsartan (Entresto)/cardiovascular agents (cardiovascular agents, other)	100	100	100	\$ 42	sacubitril/valsartan (Entresto)/cardiovascular agents (cardiovascular agents, other)	0	0	0	\$ (3)
sitagliptin phosphate (Januvia)/blood glucose regulators (antidiabetic agents)	97	100	100	\$ 37	sitagliptin phosphate (Januvia)/blood glucose regulators (antidiabetic agents)	4	0	0	\$ (8)

Specialty drugs, typically with coinsurance	On formulary	Without prior authorization	Tier 3 or lower	Average co-insurance	Specialty drugs, typically with coinsurance	On formulary	Without prior authorization	Tier 3 or lower	Average co-insurance
etanercept (Enbrel)/immunological agents (immunosuppressants)	86	2	1	30	etanercept (Enbrel)/immunological agents (immunosuppressants)	8	2	1	3
ibrutinib (Imbruvica)/antineoplastics (molecular target inhibitor)/protected class	100	2	1	30	ibrutinib (Imbruvica)/antineoplastics (molecular target inhibitor)/protected class	0	2	1	3
ustekinumab (Stelara)/immunological agents (immunological agents, other)	100	0	1	30	ustekinumab (Stelara)/immunological agents (immunological agents, other)	0	0	1	3

Medicare Part D Formularies (Table 2)

(MA-PD alone and compared to PDP, excluding SNP, for 30-day supply only)

Report on CMS formulary files (January 2025). All calculations are percentages of formularies, except for co-pay, which is in dollars, and coinsurance, which is the percentage of drug price.

Drugs selected for Medicare Drug Price Negotiation in 2027

MA-PD formulary report

Non-specialty drugs, typically with co-pay

Difference: For MA-PD formulary report relative to PDP, >0 means higher in MA-PD

Non-specialty drugs, typically with co-pay

Generic (brand name)/(USP class (USP category))/protected class	On formulary	Without prior authorization	Tier 3 or lower	Average co-pay	Generic (brand name)/(USP class (USP category))/protected class	On formulary	Without prior authorization	Tier 3 or lower	Average co-pay
fluticasone/umeclidin/vilanter (Trelegy Ellipta)/respiratory tract/pulmonary agents (respiratory tract agents, other)	98	100	100	\$ 23	fluticasone/umeclidin/vilanter (Trelegy Ellipta)/respiratory tract/pulmonary agents (respiratory tract agents, other)	-2	0	0	\$ (22)
fluticasone/vilanterol (Breo Ellipta)/respiratory tract/pulmonary agents (respiratory tract agents, other)	98	100	100	\$ 23	fluticasone/vilanterol (Breo Ellipta)/respiratory tract/pulmonary agents (respiratory tract agents, other)	-2	0	0	\$ (22)
linaclotide (Linzess)/gastrointestinal agents (anti-constipation agents)	100	100	96	\$ 46	linaclotide (Linzess)/gastrointestinal agents (anti-constipation agents)	0	0	7	\$ 0
linagliptin (Tradjenta)/blood glucose regulators (antidiabetic agents)	95	100	100	\$ 38	linagliptin (Tradjenta)/blood glucose regulators (antidiabetic agents)	0	0	0	\$ (7)
semaglutide (Ozempic)/blood glucose regulators (antidiabetic agents)	98	0	96	\$ 42	semaglutide (Ozempic)/blood glucose regulators (antidiabetic agents)	6	0	2	\$ (4)
sitagliptin phos/metformin HCl (Janumet)/blood glucose regulators (antidiabetic agents)	97	100	100	\$ 37	sitagliptin phos/metformin HCl (Janumet)/blood glucose regulators (antidiabetic agents)	4	0	0	\$ (8)

Specialty drugs, typically with coinsurance	On formulary	Without prior authorization	Tier 3 or lower	Average co-insurance	Specialty drugs, typically with coinsurance	On formulary	Without prior authorization	Tier 3 or lower	Average co-insurance
acalabrutinib (Calquence)/antineoplastics (molecular target inhibitor)/protected class	100	0	0	27	acalabrutinib (Calquence)/antineoplastics (molecular target inhibitor)/protected class	0	0	0	-
apremilast (Otezla)/dermatological agents (dermatological agents, other)	63	0	1	31	apremilast (Otezla)/dermatological agents (dermatological agents, other)	-7	0	1	5
cariprazine HCl (Vraylar)/antipsychotics (second generation atypical)/protected class	100	73	1	31	cariprazine HCl (Vraylar)/antipsychotics (second generation atypical)/protected class	0	-1	1	(7)
deutetrabenazine (Austedo)/central nervous system (central nervous system agents, other)	90	3	1	30	deutetrabenazine (Austedo)/central nervous system (central nervous system agents, other)	12	3	1	2
enzalutamide (Xtandi)/antineoplastics (antiandrogens)/protected class	100	2	1	30	enzalutamide (Xtandi)/antineoplastics (antiandrogens)/protected class	0	2	1	3
nintedanib esylate (Ofev)/respiratory tract/pulmonary agents (pulmonary fibrosis)	100	2	1	30	nintedanib Esylate (Ofev)/respiratory tract/pulmonary agents (pulmonary fibrosis)	0	2	1	3
palbociclib (Ibrance)/antineoplastics (molecular target inhibitor)/protected class	100	2	1	30	palbociclib (Ibrance)/antineoplastics (molecular target inhibitor)/protected class	0	2	1	3
pomalidomide (Pomalyst)/antineoplastics (antiangiogenic)/protected class	100	2	1	30	pomalidomide (Pomalyst)/antineoplastics (antiangiogenic)/protected class	0	2	1	3
rifaximin (Xifaxan)/antibacterials (antibacterials, other)	100	7	10	32	rifaximin (Xifaxan)/antibacterials (antibacterials, other)	0	7	10	(3)